Notícias

The Wisk, Insitu and SkyGrid acquisition still needs other regulatory approvals before a year-end close

Paramount Skydance Corporation (NASDAQ:PSKY)’s $110 billion takeover of Warner Bros. Discovery, Inc. (NASDAQ:WBD), which has an equity worth of around $81 billion plus assumed debt, has been in legal limbo for months, stalled by a 12-state antitrust case and a trial date that was not scheduled until March 2027. On September 21, one of the […]

Plus: British Columbia sues OpenAI over mass school shooting and executives flock to New York to tout lowering emissions.

Paramount's agreement with 12 state attorneys general paves the way for the company to complete its $110 billion acquisition of Warner Bros. Discovery.

Sept 21 (Reuters) - Paramount Skydance has settled with California and 11 other states that sued to block its $110 billion acquisition of Warner Bros Discovery, a ‌source familiar with the matter said on Monday, clearing one of the last ‌hurdles to a deal that would reshape Hollywood. The settlement includes the creation of independent editorial boards for CNN and CBS, ​the source said, a move aimed at safeguarding the independence of their news operations under the combined company.

Paramount won’t have to sell cable channels under the $81 billion merger poised to reshape Hollywood.

Both stocks jumped about 7% Monday morning after reports that Paramount Skydance and the California attorney general met to discuss a settlement.

Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.

FDA clearance for Abbott’s TactiFlex Duo follows the dual ablation catheter’s receipt of a European CE mark in January 2026.

Fox (FOX) is facing expanded antitrust scrutiny from the US Department of Justice over its $22 billi

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.

Alphabet stock soared the last time a judge rejected the Justice Department's bid to force it to sell part of its business.

Citi said continued advertiser spending and accelerating AI demand at AWS support its bullish view of Amazon.

Eli Lilly stock has delivered very strong gains over the past five years. Current checks give a mixed read on valuation, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside, while market based multiples look closer to fair. Eli Lilly has returned 373.6% over five years, which puts a lot of optimism into the share price and raises the bar for what counts as good value today. The expanded use of drugs like Mounjaro and Zepbound in metabolic and cardiovascular care...

The chip giant stepped back from the AI Compute Partnership program last week, less than two months after announcing it in July

The company is changing how it enforces its site reputation policy within the European Economic Area, to appease regulators and avoid a potentially hefty fine.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the...

The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone. The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class […]

KKR & Co. (NYSE:KKR) is set to pay a $250 million civil penalty after the private equity firm allegedly violated the Hart-Cottrell-Rodino Act by withholding and altering documents and failing to make required filings. The HSR Act requires M&A parties...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization

JNJ's Imaavy wins FDA approval for wAIHA, becoming the first treatment specifically indicated for the rare autoimmune disease.

The Food and Drug Administration cleared a blood test for identifying Alzheimer’s disease symptoms, which was developed by Roche and Eli Lilly.

In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...

Apple is changing its fee structure for app developers in the European Union after years of regulatory pressure over its App Store practices.

Apple has agreed to major concessions in Europe to resolve regulatory antitrust disputes, replacing its controversial per-install download fee.

Apple seeks to end a yearslong antitrust dispute over how the tech company manages its devices and App Store that included a $579 million fine.

Bristol-Myers Squibb stock has delivered a 38.1% gain over the past year, while valuation work using a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples both currently point to the shares trading at a discount to that estimate. For investors, that combination of strong recent returns and a still supportive valuation framework raises the question of how much margin of safety may remain in the current price. The 38.1% one year return shows that sentiment toward...

Sycamore Capital Management, a franchise of Victory Capital Management, released its Q2 2026 investor letter for “Sycamore Mid Cap Value Equity Strategy”. A copy of the letter can be downloaded here. Sycamore Capital’s Mid Cap Value investment team focuses on a bottom-up approach to identify undervalued businesses with growth potential. In Q2 2026, the strategy […]

Makan Delrahim made the disclosure at Politico’s California Agenda conference, according to Reuters, signaling that Paramount is willing to go beyond internal safeguards to salvage a deal that has become one of the most politically charged media mergers in years. Warner Bros. Discovery is the publicly traded parent of CNN (NASDAQ: WBD), and the merger’s fate directly determines whether Ellison’s Paramount consolidates control over both CBS News and the cable network.

mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.